Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015-0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.
Müller
S
S
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany.
Schütt
P
P
Bojko
P
P
Nowrousian
M R
MR
Hense
J
J
Seeber
S
S
Moritz
T
T
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D015994:Incidence; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine